SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

Simcere Pharma (02096) announced that the group's self-developed dual-specific antibody targeting PD-1/VEGF, SIM0689, has received the drug clinical trial approval notice issued by the Chinese National Medical Products Administration (NMPA) and is planning to conduct clinical trials for advanced solid tumors. SIM0689 is a dual-specific antibody targeting the specific sites of programmed death receptor 1 (PD-1) and vascular endothelial growth factor (VEGF), which exerts potent anti-tumor activity by relieving tumor cell immune suppression and anti-angiogenesis. In multiple humanized mouse efficacy models, SIM0689 has shown excellent anti-tumor efficacy at low doses, with overall efficacy significantly superior to similar molecules, indicating its broad application prospects for various solid tumors.